The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Open accessPublished version of a preprint
Abstract
Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations. The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients. Experimental Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and negative cases were then assessed for HER2 mutations (exons 19–20) using a sizing assay and mass spectrometry. Testing for additional recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry. ALK rearrangements and HER2 amplification were assessed by FISH. Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-negative specimens. Small insertions in exon 20 accounted for 96% (24/25) of the cases. Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775. Morphologically, 92% (23/25) were moderately or poorly differentiated ADC. HER2 mutation was not associated with concurrent HER2 amplification in 11 cases tested for both. HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no associations with sex, race, or stage. Conclusions: HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2. Clin Cancer Res; 18(18); 4910–8. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Exon 20 of EGFR and HER2 contains two major regions, the α-C helix (residues 762–766 in EGFR and 770–774 in HER2) and the loop following the α-C helix (residues 767–774 in EGFR and 775–783 in HER2)16,19,20,27.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“Together, EGFR and HER2 exon 20 mutations are found in approximately 4% of all patients with NSCLC19.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
In the citing paper
“with the A775_G776insYVMA mutation accounting for most of the mutations seen in NSCLC (17–21).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Cited by
Sorted by citations
Items 401–500 of 506
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2
Massion, P. P., Sequist, L. V. D., & Pao, W. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00051-8 · Cited by 3
Predictive Tumor Biomarkers for EGFR Inhibitors
Kim, L., Liu, G., & Tsao, M. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch28 · Cited by 2
Steiling, K. A., & Campbell, J. D. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_7 · Cited by 1
Ruan, M., Chang, C., Sun, J., Liu, L., Wang, L., Lei, B., Yan, H., Zhang, H., Xie, W., & Wang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05218-8 · Cited by 1
Yang, Y., Yang, G., Li, W., Xu, H., Hao, X., Zhang, S., Ai, X., Lei, S., & Wang, Y. (2023) · Future Oncology · doi:10.2217/fon-2022-0879 · Cited by 1
Hou, Y., Xue, X., Zhang, Z., Mai, D., Luo, W., Zhou, M., Liu, Z., & Huang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14125-9 · Cited by 1
Liu, S., Cao, R., Li, H., & Zhang, D. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2025.2580760 · Cited by 1
What is new for 2026: Challenges & updates in pulmonary pathology
Lo, Y., Armstrong, S. M., & Chang, J. C. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.106021 · Cited by 1
Molecular Alterations in Lung Cancer – Beyond EGFR, ALK and ROS1
Nath, N., Osama, M. A., Nambirajan, A., & Jain, D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014092 · Cited by 1
Ruiter, G., Le, X., Soo, R. A., Yamamoto, N., Girard, N., Wu, Y.-L., Sabari, J. K., & Nadal, E. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109378 · Cited by 1
Tanvetyanon, T., Chen, D.-T., & Gray, J. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093481 · Cited by 1
Molecular landscape of non-squamous, non-small cell carcinoma of the lung
Weiss, M. C., Leukam, M. J., & Villaflor, V. M. (2015) · Translational Cancer Research · doi:10.3978/j.issn.2218-676x.2015.08.06 · Cited by 1
Zhang, K., & Wang, H. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.10.08 · Cited by 1
HER2 mutations in Moroccan lung adenocarcinoma patients
Elghissassi, I., Boutayeb, S., Inrhaoun, H., Kettani, F., Gamra, L., Mestari, A., Jabri, L., Bensouda, Y., M’rabti, H., & Errihani, H. H. (2014) · Journal of Translational Internal Medicine · doi:10.4103/2224-4018.135614 · Cited by 1
Genomic Applications in Pulmonary Malignancies
Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1
Beau‐Faller, M., Renaud, S., Weingertner, N., Lindner, V., Emprou, C., Quyen, P. L. V., Legrain, M., Voegeli, A., Chenard, M., Pencreach, E., et al. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30031-3 · Cited by 1
Brosseau, S., Oulkhouir, Y., Naltet, C., Magnier, R., Lechapt, E., & Zalcman, G. (2016) · Current Pulmonology Reports · doi:10.1007/s13665-016-0138-8 · Cited by 1
Implications of Evolving Medical Science for Proof of Lung Cancer Causation
Frarey, L., & Martínez, J. S. (2015) · Beiträge zur Tabakforschung international · doi:10.1515/cttr-2015-0020 · Cited by 1
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201710398 · Cited by 1
Castillon, M., Bourhis, A., Quintin‐Roué, I., & Uguen, A. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000879 · Cited by 1
Genomic Applications in Pulmonary Malignancies
Büttner, R., Heydt, C., & Merkelbach‐Bruse, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_27 · Cited by 1
[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].
Ren, C., Cao, H., Zheng, J., Sun, W., & Zhou, J. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.14 · Cited by 1
Feng, Z., Liu, H., Huang, J., Tan, X., Su, C., Mo, S., Tang, J., Wang, H., Lin, Y., & Zhang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113792 · Cited by 1
CT texture features of lung adenocarcinoma with HER2 mutation
Chen, W., Gao, P., Lu, F. Y., Wang, E., Liu, H., & Li, M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13686-z · Cited by 1
Wang, Y., Hu, J., Liu, R., Li, P., Wang, L., & Yang, G. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096371951250409093625 · Cited by 1
HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules
Yin, J., Huo, S., Chen, Z., Shi, Y., Sui, Q., Wang, Q., Xu, J., & Jiang, W. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03955-3 · Cited by 1
Abdayem, P., & Planchard, D. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00107-5 · Cited by 1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Simon, E., Abdayem, P., Planchard, D., & Greillier, L. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00120-3 · Cited by 1
Cooper, A. J., & Heist, R. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.004 · Cited by 1
Peled, S., Guez-Haddad, J., Biton, N. Z., Nimrod, G., Fischman, S., Fastman, Y., & Ofran, Y. (2024) · eLife · doi:10.7554/elife.89814.2 · Cited by 1
Diagnostic moléculaire des tumeurs solides
Manceau, G., & Laurent‐Puig, P. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0445-3_4
Cretella, D. (2015) · DSpaceUnipr (University of Parma)
New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material
Eng, J., Drilon, A. E. D. C., & Paik, P. K. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1607-8_8
Self-citationStrategies in Patients with Other Molecular Alterations
D’Arcangelo, M., & Hirsch, F. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-06062-0_12
Thérapies ciblées : comment déterminer la cible ?
Remmelink, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70600-7
Pécuchet, N., Bigot, F., Henni, M., & Fabre, E. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.12.005 · Cited by 1
Other novel molecular targets in non-small cell lung cancer: It's not all about EGFR
Cruikshank, R. P., & Hughes, B. G. M. (2013) · Cancer Forum
a review of agents now under investigation
Juergens, R. A. (2013)
Chitale, D. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16304-8_8
Épidémiologie moléculaire du cancer bronchique
Guibert, N. M., Milia, J., & Mazières, J. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.01.007
SURGERY. THE GENE PROFILE OF NON-SMALL CELL LUNG CANCER AND THE INVASION OF MEDIASTINAL GANGLIA
Grigoroiu, M., Dima, S., Năstase, A., Bacalbașa, N., László, V., Klepetko, W., Popescu, I., & Régnard, J. (2014) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-19-2-14
Mileham, K. F., Ersek, J. L., Kim, E. S., & Wistuba, I. I. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch19
Chudnovsky, Y., Kumar, R. D., Schrock, A. B., Connelly, C. F., Gowen, K. A., Frampton, G. M., Erlich, R., Stephens, P. J., Miller, V. A., Ross, J. S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00037
The many facets of lung adenocarcinoma – a disease comprising distinct molecular subgroups.
Gleinig, A., Huth, S., Dahmen, U., & Dirsch, O. (2015) · Medical Research Archives · doi:10.18103/mra.v1i6.411
Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)
Portier, B. P. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_7
Mutations as Predictive Biomarkers for Adenocarcinoma
Mahadevan, N. R., & Sholl, L. M. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_11
Gusev, O., Hayashizaki, Y., & Usui, K. (2018) · Respiratory disease series · doi:10.1007/978-981-10-8144-6_18
CBNPC et autres cibles thérapeutiques (BRAF, HER2, MET, RET, NTRK...)
Percin, S. D., & Planchard, D. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30042-9
Bulbul, A., Leal, A., & Husain, H. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_6
Targeting ErbB2 aberrations in non-small cell lung cancer
Ge, X., Tariq, S., Cheng, H., & Halmos, B. (2019) · Precision Cancer Medicine · doi:10.21037/pcm.2019.09.05
McCullough, P. A., & Dieter, R. S. (2013) · Clinical Practice · doi:10.2217/cpr.13.80
Lips, C., Thiel, S., Kollmeier, J., Blum, T. G., Schäfer, M., Stephan-Falkenau, S., Streubel, A., Mairinger, T., Bauer, T. T., & Misch, D. (2021) · Der Nuklearmediziner · doi:10.1055/a-1293-2162
Progress in anti-HER2 targeted therapy of metastatic lung cancer
Xiao, X. M., & Jia, Y. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127103074
Arcila, M. E., Chang, J. C., & Tafe, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_6
Self-citationOgnerubov, N. A., & Antipova, T. S. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.1.201478
Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras)
Groves, E., Haris, N. R. M., & Greystoke, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00002-0
McCullough, P. A., Friedman, J. H., & Santos, E. S. (2013) · Clinical Practice · doi:10.2217/cpr.13.26
Yang, G., Yang, Y., Liu, R., Hu, J., Xu, H., Li, W., Hao, X., & Wang, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155240
Drug Resistance in Lung Cancer
Colarusso, C., Terlizzi, M., Pinto, A., & Sorrentino, R. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_62
The development and implementation of EGFR inhibitors in advanced NSCLC
Neuwelt, A. J., & Camidge, D. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00007-3
Cui, Y., Wang, R., Wei, Y., Hou, F., Li, H., Jiang, Y., Sun, Y., Fu, S., Zuo, L., Wang, X., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117202
Warrier, A. R., George, A., Thummar, V., & Mehta, P. (2023) · Cureus · doi:10.7759/cureus.38271
Peled, S., Guez-Haddad, J., Biton, N. Z., Nimrod, G., Fischman, S., Fastman, Y., & Ofran, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.21.550003
zheng, X., Li, H., Ying, H., Cao, M., Zhu, W., Wu, X., & Wei, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3149860/v1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Planchard, D., Simon, É., Abdayem, P., & Greillier, L. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00140-4
Treatment of Stage IV Non-small Cell Lung Cancer
Sun, T. Y., & Das, M. S. (2023) · Respiratory medicine · doi:10.1007/978-3-031-38412-7_8
Yıldırım, A. N. T., Aker, F., & Erkan, M. (2023) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1341970
Peled, S., Guez-Haddad, J., Biton, N. Z., Nimrod, G., Fischman, S., Fastman, Y., & Ofran, Y. (2024) · eLife · doi:10.7554/elife.89814
Peled, S., Guez-Haddad, J., Biton, N. Z., Nimrod, G., Fischman, S., Fastman, Y., & Ofran, Y. (2024) · eLife · doi:10.7554/elife.89814.1
Autres cibles addictives (KRAS, RET, HER2, NTRK...)
Cortot, A. B., Abdayem, P., & Planchard, D. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00090-9
20 Pathology of Metastatic Spinal and Vertebral Column Neoplasms
(2025) · Thieme Medical Publishers eBooks · doi:10.1055/b-0045-210213
黄, 熙. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541021
Liu, S., Cao, R., Li, H., & Zhang, D. (2025) · Research Square · doi:10.21203/rs.3.rs-6769788/v1
Bubendorf, L., Savic, S., & Ruiz, C. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-5195-2.00037-6
Cancer bronchique non à petites cellules avec autres mutations actionnables (BRAF, MET, HER2)
Mogenet, A., Cortot, A. B., Abdayem, P., Planchard, D., & Greillier, L. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00079-5
Ke, Z., Yang, H., Xing, M., Bi, S., & Yang, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1637973
Grempler, R., Joseph, D. P., Gan, G., Auclair, A., Tiessen, R. G., Maw, H. H., Laux, R., Wind, S., Roessner, P. M., Sadrolhefazi, B., et al. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01509-9
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047311
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047314
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047320
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19101740
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047323
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047317
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19101737
Azhar, M. S. M., Abdelkarim, A., Vijay, A., Young, R., Ahmed, S., & Dulloo, S. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109078
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Scaglione, I. M., Bonato, A., Dodi, A., Sposito, M., Eccher, S., Avancini, A., Tregnago, D., Insolda, J., Milella, M., Pilotto, S., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062643 · Cited by 1
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Complications following small-molecule inhibitors for non-small cell lung cancer
Kamali, C., & Ekman, S. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2665836
Wang, P., Wang, J., Qin, Q., Zhou, D., Huang, D., Chen, S., Zeng, S., Hong, Y., Jiang, M., & Huang, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-05359-5
Jing, R., YanDong, M. I. A. O., Daut, U. N., How, S. H., Zhang, F., & Stanslas, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00041
Elantably, D., Meerzaman, I., Hou, A. Y., Abdelhakeem, A., & Lou, Y. (2026) · Cancers · doi:10.3390/cancers18132121
Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review
Arrieta, O. G., Caballé‐Perez, E., Cabrera-Miranda, L. A., Cardona, A. F., Davila-Dupont, D., Velasco-Córdoba, M., & Treviño, L. A. C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105619
Metadata
- Authors
- Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Authors' Affiliations: 1Department of Pathology, and 2Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
- National Institutes of Health (US)
- Corresponding author
- Arcila, Maria E.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-09-15
- Volume
- 18
- Issue
- 18
- Pages
- 4910-4918
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3865806
- OpenAlex
- W2107562400
- Cited by
- 505
- References
- 48
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 36 · 2023: 40 · 2022: 39 · 2021: 52 · 2020: 42 · 2019: 30 · 2018: 42 · 2017: 30 · 2016: 23 · 2015: 43 · 2014: 37 · 2013: 31 · 2012: 4
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, lung adenocarcinoma, tyrosine kinase mutations, exon 20 insertion, never smokers, HER2 amplification, EGFR, KRAS, ALK rearrangement, molecular subtyping, clinicopathological features, molecular heterogeneity
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Prevalence, Survival Analysis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Protein Interaction Domains and Motifs, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
